| Authors: |
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Raghav KPS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Swanton C; Francis Crick Institute, London, United Kingdom., Spigel DR; Sarah Cannon Research Institute, Nashville, Tennessee., Bose R; Washington University School of Medicine, St. Louis, Missouri., Burris HA; Sarah Cannon Research Institute, Nashville, Tennessee., Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Espenschied CR; Global Scientific Affairs, Guardant Health, Redwood City, California., Grindheim JM; Genentech, Inc., South San Francisco, California., Malato J; Genentech, Inc., South San Francisco, California., Schulze K; Genentech, Inc., South San Francisco, California., Price R; Genentech, Inc., South San Francisco, California., Kurzrock R; Medical College of Wisconsin Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Milwaukee, Wisconsin. |
